Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO).

D'Angelillo RM, Francolini G, Ingrosso G, Ravo V, Triggiani L, Magli A, Mazzeo E, Arcangeli S, Alongi F, Jereczek-Fossa BA, Pergolizzi S, Pappagallo GL, Magrini SM.

Crit Rev Oncol Hematol. 2019 Jun;138:24-28. doi: 10.1016/j.critrevonc.2019.03.014. Epub 2019 Apr 1. Review.

PMID:
31092381
2.

Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.

Niazi T, Elakshar S, Stroian G.

Curr Opin Support Palliat Care. 2018 Sep;12(3):351-358. doi: 10.1097/SPC.0000000000000371. Review.

PMID:
29979320
3.

Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases.

Saluja R, Cheung P, Zukotynski K, Emmenegger U.

Urol Oncol. 2016 May;34(5):225-32. doi: 10.1016/j.urolonc.2016.02.016. Epub 2016 Mar 19. Review.

PMID:
27008982
4.

Advances in local and ablative treatment of oligometastasis in prostate cancer.

Yao HH, Hong MKh, Corcoran NM, Siva S, Foroudi F.

Asia Pac J Clin Oncol. 2014 Dec;10(4):308-21. doi: 10.1111/ajco.12256. Epub 2014 Aug 25. Review.

PMID:
25155557
5.

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT.

BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.

6.

[Radiotherapy for local disease in metastatic prostate cancer.]

Cambeiro M, Calvo FA.

Arch Esp Urol. 2018 Mar;71(3):298-305. Review. Spanish.

PMID:
29633951
7.

[(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.

Pasqualetti F, Panichi M, Sainato A, Matteucci F, Galli L, Cocuzza P, Ferrazza P, Coraggio G, Pasqualetti G, Derosa L, Sollini M, Mannelli L, Ortori S, Monzani F, Ricci S, Greco C, Fabrini MG, Erba PA.

Radiat Oncol. 2016 Jan 22;11:9. doi: 10.1186/s13014-016-0586-x.

8.

CyberKnife Stereotactic Ablative Radiotherapy as an Option of Treatment for Patients With Prostate Cancer Having Oligometastatic Lymph Nodes: Single-Center Study Outcome Evaluation.

Napieralska A, Miszczyk L, Stąpór-Fudzińska M.

Technol Cancer Res Treat. 2016 Oct;15(5):661-73. doi: 10.1177/1533034615595945. Epub 2015 Jul 24.

PMID:
26208835
9.

Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.

Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):696-702. doi: 10.1016/j.ijrobp.2016.01.032. Epub 2016 Jan 29.

10.

Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.

De Bleser E, Tran PT, Ost P.

Curr Opin Urol. 2017 Nov;27(6):587-595. doi: 10.1097/MOU.0000000000000441. Review.

PMID:
28816714
11.

Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.

Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, Tai KH, Udovicich C, Lim A, Selbie L, Hofman MS, Kron T, Moon D, Goad J, Lawrentschuk N, Foroudi F.

Eur Urol. 2018 Oct;74(4):455-462. doi: 10.1016/j.eururo.2018.06.004. Epub 2018 Jun 29.

PMID:
30227924
12.

Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.

Ost P, Jereczek-Fossa BA, Van As N, Zilli T, Tree A, Henderson D, Orecchia R, Casamassima F, Surgo A, Miralbell R, De Meerleer G.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e115-20. doi: 10.1016/j.clon.2016.04.040. Epub 2016 Apr 28.

PMID:
27133946
13.

Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report.

Markowski MC, Imus P, Wright JL, Schottenstein D, Paller CJ.

Clin Genitourin Cancer. 2017 Oct;15(5):e839-e842. doi: 10.1016/j.clgc.2017.02.001. Epub 2017 Feb 27. No abstract available.

14.

Stereotactic radiotherapy in oligometastatic cancer.

Kennedy TAC, Corkum MT, Louie AV.

Chin Clin Oncol. 2017 Sep;6(Suppl 2):S16. doi: 10.21037/cco.2017.06.20. Review.

15.

Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer.

Desai NB, Laine AM, Timmerman RD.

Br J Radiol. 2017 Feb;90(1070):20160500. doi: 10.1259/bjr.20160500. Epub 2016 Dec 23. Review.

16.

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.

Kim J, Park JS, Ham WS.

Investig Clin Urol. 2017 Sep;58(5):307-316. doi: 10.4111/icu.2017.58.5.307. Epub 2017 Aug 8. Review.

17.

The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer.

Guerrero E, Ahmed M.

Lung Cancer. 2016 Feb;92:22-8. doi: 10.1016/j.lungcan.2015.11.015. Epub 2015 Dec 2. Review.

PMID:
26775592
18.

Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.

Shultz DB, Filippi AR, Thariat J, Mornex F, Loo BW Jr, Ricardi U.

J Thorac Oncol. 2014 Oct;9(10):1426-33. doi: 10.1097/JTO.0000000000000317. Review.

19.

[Definitions of oligometastatic disease and new treatment concepts].

Kissel M, Helou J, Thariat J.

Bull Cancer. 2018 Jul - Aug;105(7-8):696-706. doi: 10.1016/j.bulcan.2018.04.012. Epub 2018 Jun 20. Review. French.

PMID:
29935914
20.

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.

Palma DA, Haasbeek CJ, Rodrigues GB, Dahele M, Lock M, Yaremko B, Olson R, Liu M, Panarotto J, Griffioen GH, Gaede S, Slotman B, Senan S.

BMC Cancer. 2012 Jul 23;12:305. doi: 10.1186/1471-2407-12-305.

Supplemental Content

Support Center